Observational studyEuropean journal of medical research2025
Plasma phenylalanine is associated with hospital mortality in acute respiratory distress syndrome: a prospective metabolic profiling cohort study.
Observational study in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Untangling amino acid metabolism in renal diseases: mechanisms, dysregulation, and critical gaps.Clinical kidney journal · 2026Review
- Circulating metabolome as key biomarkers for ventilator-associated pneumonia: Case-Control study in a tertiary care hospital of North India.International journal of critical illness and injury scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPhenylalanine accumulation is associated with inflammation, immune system activation, and oxidative stress-all of which are involved in the pathophysiology of acute respiratory distress syndrome (ARDS). This study evaluated the correlation between longitudinal changes in plasma phenylalanine levels and clinical outcomes in patients with ARDS.
methodsThis prospective observational cohort study conducted in Taiwan focused on plasma amino acid profiling in ARDS patients between February 2017 and June 2018, and again between November 2021 and October 2023. Serial changes in plasma amino acid levels and clinical variables measured at days 1, 3, and 7 after ARDS onset were compared with clinical outcomes.
resultsThis study included 214 ICU patients, including 180 patients with ARDS and 34 patients without. Among ARDS patients, the in-hospital mortality rate was 45%. Plasma phenylalanine levels were significantly higher among ARDS patients than among ICU controls at all timepoints (days 1, 3, and 7). Plasma phenylalanine levels and phenylalanine/tyrosine ratios were significantly higher among non-survivors than among ARDS survivors throughout the observation period (all p < 0.05). ARDS patients with high plasma phenylalanine levels (> 125.3 µM; 47 patients; 26.1%) presented a significantly elevated risk of organ failure (i.e., higher APACHE II and SOFA scores) as well as 28-, 60-, 90-day, and all-cause hospital mortality, compared to those with low plasma phenylalanine levels (≤ 125.3 µM; 133 patients; 73.9%) (all p < 0.05). Multivariable logistic regression analysis revealed that plasma phenylalanine levels and phenylalanine/tyrosine ratios at day 1 were independently associated with hospital mortality (adjusted OR 1.009, [95% CI 1.001-1.017], p = 0.037 and adjusted OR 2.851, [95% CI 1.045-7.780], p = 0.041, respectively). A plasma phenylalanine level of > 125.3 µM had the highest predictive value for in-hospital mortality (adjusted OR 4.825, [95% CI 1.324-17.583], p = 0.017).
conclusionsPlasma phenylalanine at the onset of ARDS is independently associated with hospital mortality. These findings indicate that phenylalanine metabolism may be disrupted early in the course of ARDS. They also indicate that plasma phenylalanine levels could serve as an early prognostic metabolic biomarker and potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.